Benlysta Back In The Spotlight With BLISS-76, But Second Phase III Still May Not Be Enough To Support Some Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
BLISS-76 shows Benlysta 10 mg/kg is efficacious in patients with systemic lupus erythematosus; HGS/GSK expect to file in first half 2010.
You may also be interested in...
Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks
The broad labeling that FDA approved for Benlysta, the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.
Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks
The broad labeling that FDA approved for Benlysta, the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.
HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions
The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.